REPL News and Press, Replimune Group Inc. From 10/15/21

BTIG analyst Kaveri Pohlman assumed coverage of Replimune Group (NASDAQ:REPL) with a Buy rating and $60 price target (PT), implying a premium of ~93% from last close. The analyst assumed coverage of 10 more Immuno-oncology companies, and believes "much of the most promising work" involves bro...

Replimune Group, Inc. has lost nearly all its share price gains since mid-October 2020 when it presented encouraging data on two of its oncolytic immunotherapy assets. A news vacuum, a secondary, and a tepid response to an early-June 2021 update to its programs are to blame. With ...

WOBURN, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced four poster presentations at the upcoming Society for Immunotherapy of Cance...

Replimune Group (REPL -10.6%) is on track to lose over a tenth of its value after the company’s first quarter earnings for fiscal 2022 came below expectations. Additionally, citing timeline changes across its pipeline, RBC Capital Markets have lowered the price target of Replimune (NAS...

Replimune Group (NASDAQ:REPL): FQ1 GAAP EPS of -$0.53 misses by $0.08. As of June 30, 2021, cash, cash equivalents and short-term investments were $458.3M, as compared to $476.3M as of March 31, 2021.  Based on the current operating plan, Replimune believes that exist...

WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that Robert Coffin, Ph.D., President and Chief Research & Development Offi...

The stock fell 12% on information suggesting RP1's weakness as monotherapy, which was doubtful, to begin with. However, the data solidified RP1's chances on its registrational trials and pointed towards other more plausible goals for the rest of the pipeline. The company has gathe...

Gainers: Ra Medical Systems (RMED) +25%, Sundial Growers (SNDL) +24%, Kindred Biosciences (KIN) +14%, Lannett (LCI) +11%, IGM Biosciences IGMS +11%.Losers: PetMed Express (PETS) -25%, SELLAS Life Sciences (SLS) -15%, Replimune  REPL ...

Replimune Group (REPL) is trading ~7.6% higher in early hours after announcing favorable interim results from a Phase 2 study for the combination RP1 (vusolimogene oderparepvec) with Opdivo (nivolumab) in a cohort of patients with skin cancer.In the CERPASS study, at the c...

High rate of complete responses in RP1 skin cancer cohorts underscore the potential for profound patient benefit and supports the ongoing registration directed development programs RP2 data confirms the signal with RP1 in anti-PD1 failed melanoma, uveal melanoma and in treating ...